AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03728465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: In the induction phase of this study nivolumab is administered as a IV infusion in combination with ipilimumab at a dose of 1 mg/kg for 4 cycles at three weeks interval and in a maintenance phase alone at a dose of 3 mg/kg every two weeks.
Study NCT03728465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: In the induction phase of this study ipilimumab is administered as a IV infusion in combination with nivolumab at a dose of 3 mg/kg for 4 cycles at three weeks interval.
Study NCT03353675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG4010
Description: 1 dose (1x1E+08) Subcutaneous injection/week over 6 weeks then 1 dose/3 weeks
Study NCT03353675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Pemetrexed/Cisplatin or Carboplatin~Pemetrexed maintenance
Study NCT03353675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 360 mg IV administration every 3 weeks
Study NCT04261556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real tDCS + CCT
Description: 40 min/day of computerised cognitive training (CCT) + 20 min/day of real anodal transcranial direct current stimulation (tDCS).~In the first 20 min of the 40 min-intervention, real anodal tDCS and CCT will be provided simultaneously.
Study NCT04261556 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS + CCT
Description: 40 min/day of computerised cognitive training (CCT) + 20 min/day of apparent (sham) tDCS.~In the first 20 min of the 40 min-intervention, sham tDCS and CCT will be provided simultaneously.
Study NCT00707785 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: 50,000 IU of Vitamin A 50,000 IU of vegetable oil
Study NCT00707785 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Description: 50,000 IU of Vitamin A 50,000 IU of vegetable oil
Study NCT02106000 — intervention group
Intervention type: DEVICE
Intervention: Inhalation profile recorder
Description: Up to three inhalation profiles will be recorded whilst inhaling with maximal effort
Study NCT00601835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine
Description: 0.5 mL, Intramuscular, single dose
Study NCT00601835 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine
Description: 0.5 mL, Intramuscular, Single dose
Study NCT04292535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo into the intranasal mucosa
Description: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer
Study NCT04292535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo into the intranasal mucosa
Description: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer
Study NCT04292535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
Study NCT04292535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
Study NCT04292535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
Study NCT04292535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
Study NCT04292535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
Study NCT04292535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 60 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
Study NCT04292535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
Study NCT04292535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 80 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
Study NCT04292535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
Study NCT04292535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
Study NCT04292535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
Study NCT04292535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 120 IU NovoLog Insulin aspart into the intranasal mucosa
Description: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
Study NCT05581017 — intervention group
Intervention type: PROCEDURE
Intervention: Preoperative biliary drainage
Description: Preoperative biliary drainage before pancreaticoduodenectomy. Might be needed if the biliary tract in obstructed and the surgery cannot be scheduled in near future.
Study NCT00323141 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventralex versus Leight Weight Vypro II prothesis
Description: Ventralex and Leight Weight Vypro II prothesis are compared.
Study NCT04528641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRAd-COV2
Description: Single intramuscular administration.
Study NCT00871910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 2 hour IV infusion on Day 1 of each 3 week cycle, administered in dose-escalating cohorts (Part 1 of the trial)
Study NCT00871910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 8 hour IV infusion on Day 1 of each 3 week cycle,in dose-escalating cohorts
Study NCT00871910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 24 hour IV infusion on Day 1 of each 3 week cycle, in dose-escalating cohorts
Study NCT00871910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 29.6 mg/m2 2 hour IV infusion on Day 1 of each 3 week cycle
Study NCT00871910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Oral aprepitant in Cycle 1 or Cycle 2, depending on the study arm: 125 mg 1 hour prior to the SCH 727965 infusion on Day 1, and 80 mg on Days 2 and 3.
Study NCT00871910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 32 mg IV 30 minutes prior to the SCH 727965 infusion on Day 1 of Cycles 1 and 2.
Study NCT00871910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral dexamethasone in Cycles 1 and 2: 12 mg 30 minutes prior to the SCH 727965 infusion on Day 1, and 8 mg in the morning on Days 2, 3, and 4.
Study NCT00446979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: HEC (hydroxyethyl cellulose) Control Gel applied vaginally twice daily for two weeks
Study NCT00446979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UC 781
Description: UC 781 0.1% or UC 781 0.25%, applied vaginally twice daily for two intermenstrual weeks
Study NCT01460173 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Divided Attention Steering Simulator (DASS)
Description: Half-hour divided attention test with steering wheel after 5 to 10 minutes of practice. Completion of three questionnaires (ESS, Young, Berlin Questionnaire).
Study NCT03836625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CareConekta
Description: CareConekta is a smartphone app that uses the phone's GPS to prospectively characterize mobility and allow for intervening in real-time. CareConekta uses the phone's built-in GPS system to record location coordinates.
Study NCT01420861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-758
Description: two GTx 758 tablets per day
Study NCT03636555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin will be given in an intranasal spray (Syntocinon Spray) twice daily (10 insufflations, 1.0 mL, 40 IU/dose) for 12 weeks
Study NCT03636555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution (contained all the ingredients in Syntocinon Spray except for oxytocin) will be given as an intranasal spray twice daily (10 insufflations, 1.0 mL/dose) for 12 weeks
Study NCT03479229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geneveve Treatment
Description: The active treatment group will receive a treatment dose of 90 J/cm\^2
Study NCT03479229 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Treatment
Description: The sham group will receive a sub-therapeutic dose of ≤ 1 J/cm\^2.
Study NCT01247324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Study NCT01247324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab-matching placebo
Study NCT01247324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Study NCT01247324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a-matching placebo
Study NCT04154475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yogurt diet
Description: 500 g yogurt/day
Study NCT04154475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dairy diet
Description: 500 g non-yogurt dairy products
Study NCT04154475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard diet
Description: 500 g soya-yogurt
Study NCT04076540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4041
Description: Administration by Oral syringe
Study NCT04076540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration by Oral syringe
Study NCT00884546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-833923
Description: Capsule, Oral, Once daily, 6 months
Study NCT00884546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-833923
Description: Capsule, Oral, Once daily, 6 months
Study NCT00884546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Capsule, Oral, Once daily, 6 months
Study NCT00884546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Capsule, Oral, Once a week, 6 months
Study NCT00884546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Powder, IV, On days 1, 4, 8, 11, 6 months
Study NCT02893319 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feeding and growth differences, 5oz vs 8oz bottle
Description: Group A: 5oz bottle Group B: 8oz bottle
Study NCT00498940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimization Testing
Description: Atrioventricular (AVD) and interventricular (VVD) delays and left ventricle lead site location were optimized after weaning off bypass (Phase I), after sternal closure (Phase II), and 12 to 24 hours (Phase III) after bypass. Intrinsic heart rate was also optimized in Phase III.
Study NCT00498940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Temporary Biventricular Pacing
Description: Continuous temporary biventricular pacing for 24 hours at a heart rate of 90 bpm or 10 bpm above intrinsic heart rate.
Study NCT01244841 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fast post MI care
Description: All post MI investigations, treatment, start of medication, information are performed within 3 days after admittance.
Study NCT01350999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3-acid ethyl esters 90 (TAK-085)
Description: Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
Study NCT01350999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic acid-ethyl (EPA)
Description: EPA-E capsules
Study NCT00668148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: Ewing's Sarcoma/PNET~10 milligrams per kilogram (mg/kg) intravenous (IV) infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle.
Study NCT00668148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: Rhabdomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle.
Study NCT00668148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: Leiomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle.
Study NCT00668148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: Adipocytic sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle.
Study NCT00668148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: Synovial sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle.
Study NCT02291146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LA Sprouts intervention
Description: see arm 1 description
Study NCT03522298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxalisib (GDC-0084)
Description: Patients will be dosed orally with paxalisib (GDC-0084) capsules (15-mg each) at the dose and schedule to which they are assigned.
Study NCT00380055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation Services
Description: Navigators (community health workers) identify and assist in overcoming barriers to appropriate cancer care.
Study NCT00380055 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cancer education
Description: Community health workers provide cancer education appropriate for Medicare participants.
Study NCT02954107 — intervention group
Intervention type: OTHER
Intervention: MRI
Study NCT02954107 — intervention group
Intervention type: OTHER
Intervention: 24h-EEG + video
Study NCT02954107 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological tests
Study NCT00215111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carbohydrate, reduced glycemic load, and a control diet
Study NCT02719548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft edge oval - Hard oval - Modified PF breast shield
Description: Treatment order:~1. soft-edge oval breast shield~2. Hard oval breast shield~3. modified PersonalFit breast shield
Study NCT02719548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified PF breast shield - Soft edge oval - Hard oval
Description: 1. modified PersonalFit breast shield~2. soft-edge oval breast shield~3. Hard oval breast shield
Study NCT02719548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hard oval - Soft edge oval - Modified PF breast shield
Description: 1. Hard oval breast shield~2. soft-edge oval breast shield~3. modified PersonalFit breast shield
Study NCT01552070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recruitment maneuver
Description: Recruitment maneuver will be performed immediately (within 2 minutes) after intubation, consisting of a continuous positive airway pressure of 40 cmH2O over 30 seconds.
Study NCT01552070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without recruit maneuver
Description: After oral intubation, each patient will be mechanically ventilated, with a tidal volume of 6mL/kg, a respiratory rate of 20 to 25 breaths/minute, a positive end-expiratory pressure (PEEP) of 5 cmH2O, and an FiO2 of 100%. PEEP titration according to FiO2 and ARDSnet.
Study NCT00447226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral lapatinib tablets or placebo tablets
Description: Subjects administered open label lapatinib, 1500 mg to be taken orally once a day, for 12 weeks. After 12 weeks, subjects with a partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST) will continue to receive open label lapatinib (1500 mg/day orally) until disease progression. Subjects who maintain stable disease will be randomized in a 1:1 ratio to enter stage 2 of the study and receive double blind therapy of either lapatinib 1500 mg/day orally or placebo. Subjects who progress on placebo will have the option to receive lapatinib 1500 mg/day orally until further progression. Those who progress on lapatinib will be withdrawn from the study.
Study NCT00447226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral lapatinib tablets or placebo tablets
Description: Subjects administered open label lapatinib, 1500 mg to be taken orally once a day, for 12 weeks. After 12 weeks, subjects with a partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST) will continue to receive open label lapatinib (1500 mg/day orally) until disease progression. Subjects who maintain stable disease will be randomized in a 1:1 ratio to enter stage 2 of the study and receive double blind therapy of either lapatinib 1500 mg/day orally or placebo. Subjects who progress on placebo will have the option to receive lapatinib 1500 mg/day orally until further progression. Those who progress on lapatinib will be withdrawn from the study.
Study NCT03984110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozurdex
Description: Intravitreal injection
Study NCT03984110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eylea
Description: Intravitreal injection
Study NCT03984110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eylea
Description: Intravitreal injection
Study NCT03373578 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: earmuffs
Description: to compare the neonate's sleep with and without earmuffs during Quiet time at the NICU
Study NCT02741622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High aerobic intensity training (HIT)
Description: One training session, high aerobic intensity training (HIT) at 90-95 % of the maximal heart rate (HRmax)
Study NCT02741622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long slow distance training (LSD)
Description: One training session, long slow distance training (LSD) at 70 % of the HRmax
Study NCT01232868 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: trivalent Influenza vaccine (TIV)
Description: 0.5 ml IM as a single dose in a prefilled syringe.
Study NCT01013129 — intervention group
Intervention type: GENETIC
Intervention: DNA analysis
Description: saliva samples will be collected from men (probands) who join the study.
Study NCT01013129 — intervention group
Intervention type: GENETIC
Intervention: polymorphism analysis
Description: we will genotype DNA samples (buccal) from all probands and conduct a traditional case-control analysis
Study NCT01013129 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: 10ml blood specimen will be obtained and processed (on probands locally-consented and/or those who have an appointment at the VA in Portland, Oregon) to allow for analyses of erythrocyte fatty acids and future nutrient and DNA analyses
Study NCT01013129 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Description: PSA results, prostate biopsy pathology reports and clinician notes related to the biopsy are reviewed for final data analysis
Study NCT01013129 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: probands are asked to complete questionnaires on 1) family history of cancer, 2) diet history over the past year, 3) employment environment and risk factors and/or 4) changes to diet, medications since enrollment in originating case control study